ACADIA Pharmaceuticals Inc.
ACAD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3 | $5 | $3 | $4 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $3 | $5 | $3 | $4 |
| Revenue | $1 | $1 | $1 | $0 |
| % Growth | 31.8% | 40.4% | 6.8% | – |
| Gross Profit | $1 | $1 | $1 | $0 |
| % Margin | 91.5% | 93.7% | 98% | 96% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 10.5% | -9.3% | -42.8% | -34.5% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 23.6% | -8.4% | -41.8% | -34.7% |
| EPS Diluted | 1.36 | -0.37 | -1.34 | -1.05 |
| % Growth | 467.6% | 72.4% | -27.6% | – |
| Operating Cash Flow | $0 | $0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | $0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |